Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Your search for Genius returned no results
Showing 1 to 15 of 16 results for genus

  1. Osimertinib with pemetrexed and platinum-based chemotherapy for untreated EGFR mutation-positive advanced non-small-cell lung cancer [ID6328]

    In development [GID-TA11408] Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Faricimab for treating macular oedema caused by retinal vein occlusion [ID6197]

    In development [GID-TA11148] Expected publication date: 14 August 2024

    Technology appraisal guidance
    In development

  3. Pembrolizumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for resectable non-small-cell lung cancer [ID5094]

    In development [GID-TA11174] Expected publication date: 16 October 2024

    Technology appraisal guidance
    In development

  4. Pembrolizumab for adjuvant treatment of resected non-small-cell lung cancer [ID3907]

    In development [GID-TA10784] Expected publication date: 16 October 2024

    Technology appraisal guidance
    In development

  5. Vibegron for treating symptoms of overactive bladder ID6300

    In development [GID-TA11348] Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Alectinib for adjuvant treatment of ALK-positive non-small-cell lung cancer [ID6368]

    In development [GID-TA11436] Expected publication date: 11 December 2024

    Technology appraisal guidance
    In development

  7. Donanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID6222]

    In development [GID-TA11221] Expected publication date: 11 September 2024

    Technology appraisal guidance
    In development

  8. Sparsentan for treating primary IgA nephropathy ID6308

    In development [GID-TA11359] Expected publication date: 11 December 2024

    Technology appraisal guidance
    In development

  9. Durvalumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for resectable non-small-cell lung cancer [ID6220]

    In development [GID-TA11197] Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Elacestrant for treating oestrogen receptor-positive, HER2-negative advanced breast cancer with an ESR1 mutation after at least 1 endocrine treatment [ID6225]

    In development [GID-TA11263] Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Treatments for non-small-cell lung cancer [ID6234]

    In development [GID-TA11289] Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Lecanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID4043]

    In development [GID-TA11220] Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease (TA223)

    Evidence-based recommendations on cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for treating intermittent claudication in adults with peripheral arterial disease.

    Technology appraisal guidance
    Published
    25 May 2011
    View recommendations

    Sections for TA223

  14. Aumolertinib for untreated EGFR mutation-positive non-small-cell lung cancer [ID4000]

    In development [GID-TA10899] Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Aducanumab for treating mild cognitive impairment and mild dementia caused by Alzheimer's disease [ID3763]

    Discontinued [GID-TA10739]

    Technology appraisal guidance
    Discontinued